Astellas Pharma Inc. - Product Pipeline Review - 2014

Date: September 30, 2014
Pages: 247
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5D6940CB87EN
Leaflet:

Download PDF Leaflet

Astellas Pharma Inc. - Product Pipeline Review - 2014
Summary

Global Markets Direct’s, ‘Astellas Pharma Inc. - Product Pipeline Review - 2014’, provides an overview of the Astellas Pharma Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Astellas Pharma Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Astellas Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Astellas Pharma Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Astellas Pharma Inc.’s pipeline products
Reasons to buy
  • Evaluate Astellas Pharma Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Astellas Pharma Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Astellas Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Astellas Pharma Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Astellas Pharma Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Astellas Pharma Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Astellas Pharma Inc. Snapshot
Astellas Pharma Inc. Overview
Key Information
Key Facts
Astellas Pharma Inc. - Research and Development Overview
Key Therapeutic Areas
Astellas Pharma Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Astellas Pharma Inc. - Pipeline Products Glance
Astellas Pharma Inc. - Late Stage Pipeline Products
Astellas Pharma Inc. - Clinical Stage Pipeline Products
Astellas Pharma Inc. - Early Stage Pipeline Products
Astellas Pharma Inc. - Drug Profiles
enzalutamide
isavuconazonium sulfate
nateglinide + DPP-4 Inhibitor
tacrolimus ER
(mirabegron + solifenacin succinate)
amenamevir
ASP-0113
bendamustine hydrochloride
beraprost sodium LA
bixalomer
degarelix
evolocumab
fidaxomicin
ipragliflozin
peficitinib
quetiapine fumarate ER
rilotumumab
romosozumab
roxadustat
solifenacin succinate
tacrolimus
ASP-1707
ASP-3652
ASP-4901
ASP-7991
ASP-8477
erlotinib hydrochloride
FG-2216
linaclotide
regadenoson
AMG-337
ASP-8273
gilteritinib
linsitinib
AGS-15E
AGS-16C3F
AGS-16M8F
AGS-67E
ASG-15ME
ASP-3325
ASP-3662
ASP-3700
ASP-5633
ASP-5878
ASP-7657
ASP-7962
ASP-8232
ASP-9226
enfortumab vedotin
mirabegron ER
OSI-027
OSI-930
Antibody Drug Conjugates for Cancer
AS-1069562
AS-1535907
AS-1669058
AS-1708727
AS-1842856
AS-1940477
AS-2034178
AS-2077715
AS-2444697
AS-2521780
AS-2575959
AS-2690168
AS-2715348
AS-2795440
ASP-1017
ASP-3258
ASP-6537
ASP-7663
ASP-9133
ASP-9726
EMSP
ESB
ESBB
FK-886
KB-425796C
Monoclonal Antibody Conjugates for Oncology
Monoclonal Antibody For Infectious Diseases
MSP
OSI-296
PQIP
Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer
Small Molecule to Inhibit TAK1 for Ovarian Cancer
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine
Small Molecules to Inhibit DAAO for Cognitive Disorders
Small Molecules to Inhibit RANKL for Osteoclastogenesis
Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema
Vaccine For RSV
ASP-2397
Drug For Alzheimer’s Disease
Drugs for Pancreatic Cancer
KB-425796A
Monoclonal Antibodies for Cancer
Small Molecule to Inhibit PDE10A for Schizophrenia
Small Molecules For Neglected Tropical Diseases
Small Molecules to Inhibit ACK1 for Cancer
Astellas Pharma Inc. - Pipeline Analysis
Astellas Pharma Inc. - Pipeline Products by Target
Astellas Pharma Inc. - Pipeline Products by Route of Administration
Astellas Pharma Inc. - Pipeline Products by Molecule Type
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action
Astellas Pharma Inc. - Recent Pipeline Updates
Astellas Pharma Inc. - Dormant Projects
Astellas Pharma Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Astellas Pharma Inc. - Company Statement
Astellas Pharma Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Astellas Pharma Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES


Astellas Pharma Inc., Key Information
Astellas Pharma Inc., Key Facts
Astellas Pharma Inc. - Pipeline by Indication, 2014
Astellas Pharma Inc. - Pipeline by Stage of Development, 2014
Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2014
Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2014
Astellas Pharma Inc. - Partnered Products in Pipeline, 2014
Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2014
Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2014
Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
Astellas Pharma Inc. - Pre-Registration, 2014
Astellas Pharma Inc. - Filing rejected/Withdrawn, 2014
Astellas Pharma Inc. - Phase III, 2014
Astellas Pharma Inc. - Phase II, 2014
Astellas Pharma Inc. - Phase I, 2014
Astellas Pharma Inc. - IND/CTA Filed, 2014
Astellas Pharma Inc. - Preclinical, 2014
Astellas Pharma Inc. - Discovery, 2014
Astellas Pharma Inc. - Pipeline by Target, 2014
Astellas Pharma Inc. - Pipeline by Route of Administration, 2014
Astellas Pharma Inc. - Pipeline by Molecule Type, 2014
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2014
Astellas Pharma Inc. - Recent Pipeline Updates, 2014
Astellas Pharma Inc. - Dormant Developmental Projects,2014
Astellas Pharma Inc. - Discontinued Pipeline Products, 2014
Astellas Pharma Inc., Other Locations
Astellas Pharma Inc., Subsidiaries
Astellas Pharma Inc., Key Manufacturing Facilities

LIST OF FIGURES


Astellas Pharma Inc. - Pipeline by Top 10 Indication, 2014
Astellas Pharma Inc. - Pipeline by Stage of Development, 2014
Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2014
Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2014
Astellas Pharma Inc. - Partnered Products in Pipeline, 2014
Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2014
Astellas Pharma Inc. - Pipeline by Top 10 Target, 2014
Astellas Pharma Inc. - Pipeline by Top 10 Route of Administration, 2014
Astellas Pharma Inc. - Pipeline by Top 10 Molecule Type, 2014
Astellas Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014

Ask Your Question

Astellas Pharma Inc. - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: